Georgia's Online Cancer Information Center

Find A Clinical Trial

A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia

Status
Active
Cancer Type
Acute Lymphoblastic Leukemia
Trial Phase
Phase II
Eligibility
1 to 21, Male and Female
Study Type
Treatment
NCD ID
NCT02723994
Protocol IDs
INCB 18424-269 (primary)
NCI-2016-01687
AALL1521
Study Sponsor
Incyte Corporation

Summary

This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent

chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the

study will optimize the dose of study drug (ruxolitinib) in combination with the

chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and

ruxolitinib at the recommended dose determined in Part 1.

Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.